Bertelmann, Thomas

[["dc.bibliographiccitation.firstpage","2271"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Diabetes therapy"],["dc.bibliographiccitation.lastpage","2289"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Ziemssen, Focke"],["dc.contributor.author","Wachtlin, Joachim"],["dc.contributor.author","Kuehlewein, Laura"],["dc.contributor.author","Gamulescu, Maria-Andreea"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Feucht, Nikolaus"],["dc.contributor.author","Voegeler, Jessica"],["dc.contributor.author","Koch, Mirja"],["dc.contributor.author","Liakopoulos, Sandra"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Spital, Georg"],["dc.date.accessioned","2020-12-10T14:14:40Z"],["dc.date.available","2020-12-10T14:14:40Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1007/s13300-018-0513-2"],["dc.identifier.eissn","1869-6961"],["dc.identifier.issn","1869-6953"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15572"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/71434"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Intravitreal Ranibizumab Therapy for Diabetic Macular Edema in Routine Practice: Two-Year Real-Life Data from a Non-interventional, Multicenter Study in Germany"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","604"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Current Eye Research"],["dc.bibliographiccitation.lastpage","614"],["dc.bibliographiccitation.volume","45"],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Quiering, Claudia"],["dc.contributor.author","Vögeler, Jessica"],["dc.contributor.author","Priglinger, Siegfried"],["dc.contributor.author","Lang, Gabriele E."],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Wolf, Armin"],["dc.contributor.author","Rehak, Matus"],["dc.date.accessioned","2021-04-14T08:26:42Z"],["dc.date.available","2021-04-14T08:26:42Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1080/02713683.2019.1679839"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82046"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1460-2202"],["dc.relation.issn","0271-3683"],["dc.title","Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: Post-hoc Analysis from the COMRADE Trials"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e933"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Acta Ophthalmologica"],["dc.bibliographiccitation.lastpage","e941"],["dc.bibliographiccitation.volume","96"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Rehak, Matus"],["dc.contributor.author","Wolf, Armin"],["dc.contributor.author","Berk, Hüsnü"],["dc.contributor.author","Eter, Nicole"],["dc.contributor.author","Lang, Gabriele E."],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Quiering, Claudia"],["dc.contributor.author","Rose, Uwe"],["dc.contributor.author","Hoerauf, Hans"],["dc.date.accessioned","2020-12-10T18:26:52Z"],["dc.date.available","2020-12-10T18:26:52Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1111/aos.13770"],["dc.identifier.issn","1755-375X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76197"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1092"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","British Journal of Ophthalmology"],["dc.bibliographiccitation.lastpage","1097"],["dc.bibliographiccitation.volume","102"],["dc.contributor.author","Paul, Christoph"],["dc.contributor.author","Heun, Christine"],["dc.contributor.author","Müller, Hans-Helge"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Wachtlin, Joachim"],["dc.contributor.author","Kaymak, Hakan"],["dc.contributor.author","Mennel, Stefan"],["dc.contributor.author","Koss, Michael Janusz"],["dc.contributor.author","Fauser, Sascha"],["dc.contributor.author","Maier, Mathias M"],["dc.contributor.author","Schumann, Ricarda G"],["dc.contributor.author","Mueller, Simone"],["dc.contributor.author","Chang, Petrus"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Kazerounian, Sara"],["dc.contributor.author","Szurman, Peter"],["dc.contributor.author","Lommatzsch, Albrecht"],["dc.contributor.author","Bertelmann, Thomas"],["dc.date.accessioned","2020-12-10T18:37:12Z"],["dc.date.available","2020-12-10T18:37:12Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1136/bjophthalmol-2017-310874"],["dc.identifier.eissn","1468-2079"],["dc.identifier.issn","0007-1161"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76873"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Calculating the individual probability of successful ocriplasmin treatment in eyes with VMT syndrome: a multivariable prediction model from the EXPORT study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2167"],["dc.bibliographiccitation.journal","Clinical Ophthalmology"],["dc.bibliographiccitation.lastpage","2179"],["dc.bibliographiccitation.volume","Volume 13"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Ziemssen, Focke"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Voegeler, Jessica"],["dc.contributor.author","Koch, Mirja"],["dc.contributor.author","Eter, Nicole"],["dc.contributor.author","Liakopoulos, Sandra"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Spital, Georg"],["dc.date.accessioned","2020-12-10T18:43:01Z"],["dc.date.available","2020-12-10T18:43:01Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.2147/OPTH.S209253"],["dc.identifier.eissn","1177-5483"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78165"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.relation.eissn","1177-5483"],["dc.title","Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","258"],["dc.bibliographiccitation.journal","American Journal of Ophthalmology"],["dc.bibliographiccitation.lastpage","267"],["dc.bibliographiccitation.volume","169"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Weiss, Claudia"],["dc.contributor.author","Paulus, Eva-Maria"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Puri, Pankaj"],["dc.contributor.author","Berk, Husnu"],["dc.contributor.author","Eter, Nicole"],["dc.contributor.author","Wiedemann, Peter"],["dc.contributor.author","Lang, Gabriele E."],["dc.contributor.author","Rehak, Matus"],["dc.contributor.author","Wolf, Armin"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.date.accessioned","2018-11-07T10:09:02Z"],["dc.date.available","2018-11-07T10:09:02Z"],["dc.date.issued","2016"],["dc.description.abstract","PURPOSE: To compare the efficacy and safety of the European labels of ranibizumab 0.5 mg vs dexamethasone 0.7 mg in patients with macular edema secondary to central retinal vein occlusion (CRVO). DESIGN: Phase IIIb, multicenter, double-masked, randomized clinical trial. METHODS: Patients were randomized (1:1) to receive either monthly ranibizumab followed by pro re nata (PRN) treatment (n = 124) or 1 sustained-release dexamethasone implant followed by PRN sham injections (n = 119). Main outcomes were mean average change in best-corrected visual acuity (BCVA) from baseline to month 1 through month 6, mean change in BCVA, and adverse events (AEs). RESULTS: Of 243 patients, 185 (76.1%) completed the study. No difference was observed in BCVA between ranibizumab and dexamethasone at months 1 and 2. From month 3 to month 6, there was significant difference in BCVA gains in favor of ranibizumab. At month 6, mean average BCVA gain was significantly higher with ranibizumab than with dexamethasone (12.86 vs 2.96 letters; difference 9.91 letters, 95% confidence interval [6.51-43.30]; P < .0001). Mean injection number of ranibizumab was 4.52. Ocular AEs were reported in more patients in the dexamethasone than in the ranibizumab group (86.6% vs 55.6%). CONCLUSIONS: Using the European labels, similar efficacy was observed for ranibizumab and dexamethasone at months 1 and 2. However, ranibizumab maintained its efficacy throughout the study, whereas dexamethasone declined from month 3 onward. The main limitation of the study was that dexamethasone patients received only a single treatment during the 6-month study. In clinical practice, dexamethasone retreatment may be required earlier than 6 months. Safety findings were similar to those previously reported. (C) 2016 Elsevier Inc. All rights reserved."],["dc.description.sponsorship","NOVARTIS PHARMA GMBH, GERMANY"],["dc.identifier.doi","10.1016/j.ajo.2016.04.020"],["dc.identifier.isi","000383637300027"],["dc.identifier.pmid","27163237"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39587"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","1879-1891"],["dc.relation.issn","0002-9394"],["dc.title","Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1359"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Graefe s Archive for Clinical and Experimental Ophthalmology"],["dc.bibliographiccitation.lastpage","1367"],["dc.bibliographiccitation.volume","255"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Wachtlin, Joachim"],["dc.contributor.author","Mennel, Stefan"],["dc.contributor.author","Koss, Michael Janusz"],["dc.contributor.author","Maier, Mathias M."],["dc.contributor.author","Schumann, Ricarda G."],["dc.contributor.author","Kazerounian, Sara"],["dc.contributor.author","Daniel, Hanna"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.date.accessioned","2018-11-07T10:22:11Z"],["dc.date.available","2018-11-07T10:22:11Z"],["dc.date.issued","2017"],["dc.description.abstract","Purpose To evaluate the agreement and predictability of ocriplasmin treatment effects among retinal experts (raters) by assessment of retinal imaging data of eyes treated for vitreomacular traction in nine different centers in Germany and Austria. Retrospective cohort study. Combined confocal near-infrared scanning laser ophthalmoscopy and spectral-domain optical coherence tomography images (SpectralisA (R) device, Heidelberg Engineering GmbH, Germany) from 136 eyes of 135 subjects were reviewed by 14 raters using an internet-based grading database and a standardized questionnaire. In addition to the images taken within 2 days prior to treatment, age, gender, and lens status were disclosed to the raters. Treatment success was defined as a complete cleavage of the posterior vitreous cortex at day 28 +/- 5. Main outcome was the agreement and predictability among raters for assessment of treatment success. Raters generally accepted starting ocriplasmin treatment (chance for treatment success ae 1%) in 22.4 to 69.1% (median 53.2%) of eyes (moderate intra- and interrater agreements with kappa-values of 0.6 and 0.48). The likelihood for a high potential treatment success (equal or higher than 25%) was judged by the raters in 43.4% to 86.0% (median 62.6%) of eyes (moderate intra- and fair interrater agreements with kappa-values of 0.56 and 0.22). Allocating eyes for high potential treatment success overall increased the odds by 3.07, with odds ratios of single raters up to 4.06 to 6.16. These results underscore the importance of training health care providers in the evaluation of retinal imaging data and also to define characteristic morphological features better in the presence of vitreoretinal interface diseases. The better results of single raters in the predictability of treatment success by the allocation of eyes in the high-potential group indicates the high relevance of the meticulous analysis of retinal images."],["dc.identifier.doi","10.1007/s00417-017-3657-2"],["dc.identifier.isi","000403937600011"],["dc.identifier.pmid","28389700"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42231"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1435-702X"],["dc.relation.issn","0721-832X"],["dc.title","The predictability of ocriplasmin treatment effects: is there consensus among retinal experts? Results from the EXPORT study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e10"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Acta Ophthalmologica"],["dc.bibliographiccitation.lastpage","e18"],["dc.bibliographiccitation.volume","96"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Berk, Hüsnü"],["dc.contributor.author","Eter, Nicole"],["dc.contributor.author","Lang, Gabriele E."],["dc.contributor.author","Rehak, Matus"],["dc.contributor.author","Taylor, Simon R."],["dc.contributor.author","Wolf, Armin"],["dc.contributor.author","Weiss, Claudia"],["dc.contributor.author","Paulus, Eva-Maria"],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Hoerauf, Hans"],["dc.date.accessioned","2020-12-10T18:26:52Z"],["dc.date.available","2020-12-10T18:26:52Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1111/aos.13381"],["dc.identifier.issn","1755-375X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76196"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1252"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Retina"],["dc.bibliographiccitation.lastpage","1260"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Paul, Christoph"],["dc.contributor.author","Heun, Christine"],["dc.contributor.author","Müller, Hans H."],["dc.contributor.author","Fauser, Sascha"],["dc.contributor.author","Kaymak, Hakan"],["dc.contributor.author","Kazerounian, Sara"],["dc.contributor.author","Sekundo, Walter"],["dc.contributor.author","Mennel, Stefan"],["dc.contributor.author","Meyer, Carsten H."],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Koss, Michael J."],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Bertelmann, Thomas"],["dc.date.accessioned","2020-12-10T18:19:55Z"],["dc.date.available","2020-12-10T18:19:55Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1097/IAE.0000000000001371"],["dc.identifier.issn","0275-004X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75425"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","IMPACT OF VITREORETINAL INTERFACE ARCHITECTURE ON SUCCESSFUL VITREOMACULAR TRACTION RESOLUTION IN EYES SCHEDULED FOR INTRAVITREAL OCRIPLASMIN THERAPY"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]